Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Does The Market Size Of The Axial Spondyloarthritis (axSpA) Industry Compare Between 2025 And 2029?
The axial spondyloarthritis (axspa) market size has experienced significant expansion in recent years. It is anticipated to increase from $6.08 billion in 2024 to $6.56 billion in 2025, at a compound annual growth rate (CAGR) of 8.0%. The growth observed in previous periods can be linked to enhanced diagnostic criteria, developments in biological treatments, growing awareness of the disease, advances in genetic research, and progress in clinical trials.
The market size for axial spondyloarthritis (axspa) is anticipated to demonstrate significant expansion in the foreseeable future. It is projected to increase to $9.03 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.3%. This expected growth during the forecast period can be attributed to advancements in biomarker identification, the availability of tailored therapies, the integration of digital health solutions, an expansion of treatment options, and supportive healthcare policy. Prominent trends for the forecast period encompass early intervention strategies, a focus on patient-centric care, the implementation of telemedicine and remote consultations, continued research into disease mechanisms, and an emphasis on shared decision-making.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
Which Drivers Are Shaping The Axial Spondyloarthritis (axSpA) Industry’s Market Share?
The rising occurrence of spondyloarthritis is projected to stimulate the expansion of the axial spondyloarthritis (axSpa) market in the coming period. Spondyloarthritis is a chronic condition primarily affecting the axial skeleton, including the spine and sacroiliac joints. The escalating cases of spondyloarthritis (axSpA) can be attributed to the expanding aging population and spinal injuries resulting from even minor falls or other incidents, for which diverse treatments are offered to manage pain, control inflammation, and enhance the quality of life for patients suffering from axSpA. For example, in June 2023, according to Versus Arthritis’s Musculoskeletal Health Report 2023, a UK-based charity dedicated to supporting people with arthritis, approximately 60,000 individuals were afflicted with axial spondyloarthritis as of 2022, and around 2,200 adults receive a new diagnosis for this condition annually. Consequently, the increasing prevalence of axial spondyloarthritis (axSpa) is driving the growth of the axial spondyloarthritis (axSpa) market.
What Are The Major Segment Types Covered In The Axial Spondyloarthritis (axSpA) Market?
The axial spondyloarthritis (axspa)market covered in this report is segmented –
1) By Types: Ankylosing Spondylitis (AS); Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF); Anti-Interleukin Therapy (IL); Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets; Injections
4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors; Non-Steroidal Anti-Inflammatory Drugs (NSAID); Conventional Disease Modifying Anti-Rheumatic Drugs; Glucocorticoids; Interleukin Blockers
5) By End-Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores
Subsegments:
1) By Ankylosing Spondylitis (AS): Early-stage AS; Advanced-stage AS
2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA; Asymptomatic nr-axSpA
What Trends Are Expected To Drive The Axial Spondyloarthritis (axSpA) Market?
A key trend gaining traction in the axial spondyloarthritis (axSpA) market involves product innovations. Major companies operating within the axial spondyloarthritis (axSpA) market are developing new medications to sustain their market presence. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, obtained marketing authorization approval from the New European Commission for BIMZELX (bimekizumab). This drug is intended for treating adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who present objective indicators of inflammation, such as elevated C-reactive protein. These authorizations from the European Union (EU) represent the drug’s initial global marketing licenses for axial spondyloarthritis.
Who Are The Key Multinational Companies Dominating The Axial Spondyloarthritis (axSpA) Market?
Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
Which Global Regions Are Influencing The Competitive Landscape Of The Axial Spondyloarthritis (axSpA) Market?
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Axial Spondyloarthritis (axSpA) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp
Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2025, By The Business Research Company
Axial Flow Pump Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/axial-flow-pump-global-market-report
Satellite Transponders Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/satellite-transponders-global-market-report
Ankylosing Spondylitis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model